Tysabri May Launch At Higher Price With Added Efficacy Data, RiskMAP Cost
Executive Summary
Biogen Idec/Elan appear poised to market their re-approved multiple sclerosis therapy Tysabri (natalizumab) at a higher price than when it was first introduced
You may also be interested in...
Tysabri price jumps
The price of Biogen Idec/Elan's multiple sclerosis treatment Tysabri (natalizumab) upon relaunch in July will be 20.8% higher than when it was first approved in November 2004, according to information on Elan's website. Tysabri's new wholesale acquisition cost will be $2,184.62 per vial compared to $1,808 in 2004. FDA reapproved natalizumab June 5 with an extensive risk management program to prevent cases of progressive multifocal leukoencephalopathy. Biogen/Elan have attributed higher pricing to additional costs associated with administering the risk management plan as well as the inclusion of new efficacy data in labeling (1"The Pink Sheet" June 12, 2006, p. 8)...
Tysabri price jumps
The price of Biogen Idec/Elan's multiple sclerosis treatment Tysabri (natalizumab) upon relaunch in July will be 20.8% higher than when it was first approved in November 2004, according to information on Elan's website. Tysabri's new wholesale acquisition cost will be $2,184.62 per vial compared to $1,808 in 2004. FDA reapproved natalizumab June 5 with an extensive risk management program to prevent cases of progressive multifocal leukoencephalopathy. Biogen/Elan have attributed higher pricing to additional costs associated with administering the risk management plan as well as the inclusion of new efficacy data in labeling (1"The Pink Sheet" June 12, 2006, p. 8)...
Tysabri Out Of Remission; Returns With Updated Indication, Risk Management
The indication for Biogen Idec/Elan's re-approved multiple sclerosis therapy Tysabri (natalizumab) stops short of limiting it to use as a second-line therapy